Are Peptides Legal in Canada?
Short version: in Canada, research peptides occupy a specific legal lane: lawful to sell and buy as laboratory research materials, not lawful to sell as medicine. Understanding that lane explains almost everything about how this market works, including why every product in it is sold for research use. This is general information, not legal advice.
View product →Findings
- Most research peptides (BPC-157, retatrutide, GHK-Cu and similar) are not controlled substances in Canada.
- They are lawful to sell and buy as laboratory research materials; they are not approved medicines.
- The deciding line is intended use: supplied for laboratory research, they are ordinary research materials, which is why every product is labelled for research use only.
- Ordering from a Canadian supplier is an ordinary domestic purchase, shipped to every province.
The lane, precisely
Most research peptides (BPC-157, retatrutide, MOTS-c, GHK-Cu and similar) are not controlled substances in Canada. They are not scheduled the way narcotics or steroids are. What they also are not is approved drugs: none of them holds a Health Canada authorization.
Under the Food and Drugs Act, selling an unapproved substance for human consumption is prohibited. Supplying the same substance for laboratory research is not. That is the entire legal architecture of this industry, and it is why research peptides, ours included, are labelled research-use-only and described without medical claims: that framing is what lets the research supply industry operate.
Buying: what this means for you
Purchasing research materials from a Canadian supplier for research purposes is an ordinary domestic transaction. The obligations sit mostly on the seller’s side: honest labelling, no therapeutic claims, no human-use marketing.
Ordering research peptides in Canada
Most research peptides are supplied as lyophilised (freeze-dried) powder in sealed vials, labelled by compound and quantity, for laboratory work such as receptor binding studies, cell culture and analytical reference. Research interest spans tissue repair (BPC-157), metabolic signalling (retatrutide and MOTS-c) and skin and connective tissue biology (GHK-Cu). Certificates of analysis from independent laboratories are published for each compound on the lab reports page, with purity above 99 percent.
Vistara Labs supplies research peptides to researchers in every province, each vial labelled for research use only and described without medical claims. Questions about a compound or an order are welcome at [email protected].
Frequently asked questions
Are peptides legal to buy in Canada?
Research peptides may be lawfully bought and sold in Canada as laboratory research materials. They are not approved drugs and cannot be sold for human use.
Is retatrutide legal in Canada?
Retatrutide has no Health Canada approval, so it cannot be sold as a medicine. It is supplied lawfully as a research material.
Do peptide orders from Vistara Labs go through customs?
No. Every order ships from within Canada, so there is no customs step, and each parcel travels as an ordinary domestic delivery.
This article is general information about the Canadian regulatory landscape, not legal advice.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
References
Most published BPC-157 work is preclinical. A 2025 systematic review screened 544 records and included 36 studies — 35 preclinical and one clinical. The human reports below are small and uncontrolled, and all three appear in the same journal.
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewSystematic review; 544 records screened, 36 studies included — 35 preclinical and 1 clinical.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainRetrospective chart review, 17 patients (16 followed up by telephone); no control group, no blinding, no validated outcome instrument.
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot StudyUncontrolled pilot, 12 women with interstitial cystitis; no placebo group or blinding.
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot StudySafety pilot, 2 adults given intravenous BPC-157; preliminary tolerability observations only.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
